Very late relapse with rapid BCR-ABL1 elevation after more than seven years of treatment-free remission with undetectable molecular residual disease in chronic myeloid leukaemia

被引：1
|
作者：
Katagiri, Seiichiro [1 ]
Gotoh, Akihiko [1 ]
Ohyashiki, Kazuma [1 ]
机构：
[1] Tokyo Med Univ, Dept Hematol, Tokyo, Japan
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 188卷 / 02期
关键词：
chronic myeloid leukaemia; imatinib; treatment-free remission; late relapse; BCR-ABL1; CHRONIC MYELOGENOUS LEUKEMIA; CML PATIENTS; IMATINIB DISCONTINUATION;
D O I：
10.1111/bjh.16285
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：332 / 334
页数：3
相关论文
共 7 条
  • [1] BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase
    Hwan Kim, Dennis Dong
    Simon Kim, Taehyung
    Atenafu, Eshetu G.
    Novitzky Basso, Igor
    Forrest, Donna
    Bence-Bruckler, Isabelle
    Savoie, Lynn
    Busque, Lambert
    Keating, Mary-Margaret
    Delage, Robert
    Xenocostas, Anargyros
    Liew, Elena
    Paulson, Kristjan
    Stockley, Tracy
    Laneuville, Pierre
    Lipton, Jeffrey H.
    Kamel-Reid, Suzanne
    Leber, Brian
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (01) : 136 - 145
  • [2] Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia
    Shanmuganathan, Naranie
    Pagani, Ilaria S.
    Ross, David M.
    Park, Sahee
    Yong, Agnes S. M.
    Braley, Jodi A.
    Altamura, Haley K.
    Hiwase, Devendra K.
    Yeung, David T.
    Kim, Dong-Wook
    Branford, Susan
    Hughes, Timothy P.
    BLOOD, 2021, 137 (09) : 1196 - 1207
  • [3] Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations
    Claudiani, Simone
    Apperley, Jane F.
    Khan, Afzal
    Khorashad, Jamshid
    Milojkovic, Dragana
    HAEMATOLOGICA, 2020, 105 (05) : E225 - E227
  • [4] Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
    Marce, Silvia
    Xicoy, Blanca
    Garcia, Olga
    Cabezon, Marta
    Estrada, Natalia
    Velez, Patricia
    Boque, Concepcion
    Sagues, Miguel
    Angona, Anna
    Teruel-Montoya, Raul
    Ferrer-Marin, Francisca
    Amat, Paula
    Hernandez-Boluda, Juan Carlos
    Ibarra, Mariana M.
    Anguita, Eduardo
    Cortes, Montserrat
    Fernandez-Ruiz, Andres
    Fontanals, Sandra
    Zamora, Lurdes
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (14)
  • [5] E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy
    Claudiani, Simone
    Apperley, Jane F.
    Gale, Robert Peter
    Clark, Richard
    Szydlo, Richard
    Deplano, Simona
    Palanicawandar, Renuka
    Khorashad, Jamshid
    Foroni, Letizia
    Milojkovic, Dragana
    HAEMATOLOGICA, 2017, 102 (08) : E297 - E299
  • [6] Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission
    Lu, Liu
    Kok, Chung Hoow
    Dang, Phuong
    Branford, Susan
    Saunders, Verity A.
    Shanmuganathan, Naranie
    Ross, David M.
    Hughes, Timothy P.
    Yeung, David T. O.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (03) : 600 - 603
  • [7] Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript
    Dereme, Julien
    Voruz, Sophie
    Solly, Francoise
    Schoumans, Jacqueline
    Blum, Sabine
    ANNALS OF HEMATOLOGY, 2024, 103 (03) : 1027 - 1029
1